Medpace Holdings, Inc. $MEDP Position Boosted by Aviva PLC

Aviva PLC grew its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 58.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,883 shares of the company’s stock after purchasing an additional 1,064 shares during the period. Aviva PLC’s holdings in Medpace were worth $905,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Geneos Wealth Management Inc. lifted its position in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares in the last quarter. Brooklyn Investment Group grew its holdings in shares of Medpace by 244.8% during the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock valued at $30,000 after acquiring an additional 71 shares in the last quarter. Whittier Trust Co. increased its stake in shares of Medpace by 47.3% in the first quarter. Whittier Trust Co. now owns 109 shares of the company’s stock worth $33,000 after acquiring an additional 35 shares during the last quarter. IFP Advisors Inc raised its holdings in shares of Medpace by 223.3% during the second quarter. IFP Advisors Inc now owns 194 shares of the company’s stock worth $61,000 after acquiring an additional 134 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Medpace during the first quarter worth $60,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Down 1.1%

Shares of MEDP stock opened at $591.32 on Friday. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $625.00. The business’s 50 day moving average is $537.32 and its two-hundred day moving average is $420.81. The company has a market cap of $16.66 billion, a PE ratio of 41.35, a price-to-earnings-growth ratio of 2.67 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The business had revenue of $659.90 million during the quarter, compared to analysts’ expectations of $640.49 million. During the same period in the previous year, the company earned $3.01 earnings per share. Medpace’s revenue for the quarter was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, equities analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on the company. UBS Group downgraded Medpace from a “neutral” rating to a “sell” rating and boosted their target price for the company from $300.00 to $305.00 in a research note on Tuesday, July 29th. TD Cowen boosted their price target on Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a research note on Friday, October 24th. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a report on Friday, October 31st. Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. Finally, Rothschild & Co Redburn downgraded shares of Medpace from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $342.00 to $474.00 in a research report on Wednesday, September 3rd. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have issued a Hold rating and four have given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $487.18.

Insider Activity

In related news, President Jesse J. Geiger sold 21,503 shares of the business’s stock in a transaction dated Wednesday, November 5th. The stock was sold at an average price of $595.66, for a total transaction of $12,808,476.98. Following the completion of the transaction, the president owned 15,000 shares of the company’s stock, valued at approximately $8,934,900. The trade was a 58.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Fred B. Davenport, Jr. sold 5,972 shares of the stock in a transaction that occurred on Thursday, October 30th. The shares were sold at an average price of $581.88, for a total value of $3,474,987.36. Following the sale, the director owned 3,498 shares of the company’s stock, valued at approximately $2,035,416.24. The trade was a 63.06% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 134,211 shares of company stock worth $74,459,958. Insiders own 20.30% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.